Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma

NCT06446154 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Immune Checkpoint Inhibitors
Anti-angiogenic Therapy
Second-line Treatment

Interventions

DRUG: Fruquintinib

Sponsor

Sun Yat-sen University

Collaborators

[object Object]